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Long-term topical corticosteroid use and risk of skin 1 
cancer: A systematic review  2 
 3 
Executive Summary 4 
Background: Topical corticosteroids (TCS) are one of the most commonly prescribed medicines in 5 
dermatology and the mainstay of atopic dermatitis treatment and other skin conditions such as 6 
psoriasis. They are often required for months or years to control the disease and ultimately restore 7 
patients’ quality of life. In some patients, TCS may have a local immunosuppressive effect and 8 
theoretically may increase the risk of skin cancer, whilst on the other hand TCS may decrease the risk 9 
of skin cancer in patients where TCS are used to treat inflammatory skin disease. To date no 10 
systematic review has been performed to collate evidence of the effect of long-term TCS use on the 11 
risk of skin cancer. 12 
Objectives: The objective of this systematic review was to synthesize the available research 13 
evidence to determine the risk of skin cancer in patients on long-term use of TCS.  14 
Inclusion Criteria:  15 
Types of participants 16 
This review considered studies that included people, of all ages, genders and ethnicities. Participants 17 
with HIV, transplant participants or participants with genetic diseases (for example Gorlin-Goltz 18 
syndrome) were also considered eligible for the review. 19 
 20 
Types of intervention 21 
This review considered studies that evaluate long-term use of topical corticosteroids. We define here 22 
‘long-term’ as using TCS more than once a week for a month or longer. 23 
 24 
Types of studies 25 
This review considered cohort, cross-sectional and case-control observational studies exploring an 26 
association between the stated intervention and outcomes.  27 
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 28 
Types of outcomes 29 
The primary outcome measures of interest were: non-melanoma skin cancer (keratinocyte carcinoma), 30 
cutaneous squamous cell carcinoma (cSSC), basal cell carcinoma (BCC) or melanoma skin cancer. 31 
Genital and oral skin cancers are considered to be slightly different so we did not include them in this 32 
review. 33 
Search Strategy: We performed a comprehensive search of MEDLINE, EMBASE and LILACS in 34 
February 2016 on 9th November 2017 to identify observational epidemiological studies assessing the 35 
associations between long-term TCS use and skin cancer. We also searched EThOS at the British 36 
library (http://ethos.bl.uk)  and three drug safety databases to identify unpublished work. The titles, 37 
abstracts and full text identified from the search were assessed independently by two authors against 38 
pre-specified inclusion/exclusion criteria. 39 
Methodological Quality: Methodological quality was not assessed as no articles were found 40 
which met the inclusion criteria. 41 
Data extraction: Data extraction was not possible as no articles were found which met the inclusion 42 
criteria. 43 
Data Synthesis: It was not possible to complete data synthesis as no articles were found which 44 
met the inclusion criteria. 45 
Results: A total of 1703 potentially relevant studies were identified following a comprehensive 46 
electronic search. After abstract and title screening, 51 full texts were assessed for eligibility criteria. 47 
Of these, no study met the inclusion criteria. No additional records were identified from searching 48 
unpublished literature.   49 
Conclusions: We did not find any studies that might help us establish if long-term TCS use is 50 
associated with skin cancer. Future research using primary care databases might give a better 51 
understanding regarding long-term use of TCS and skin cancer.  52 
Keywords: Basal cell carcinoma; melanoma; non-melanoma; squamous cell carcinoma; topical 53 
corticosteroids. 54 
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Background 55 
Topical corticosteroids (TCS) are used to reduce inflammation and are one of the most commonly 56 
prescribed medicines in dermatology. They were first used successfully by Sulzberger and Witten in 57 
1952 and their success marked a cornerstone in the history of dermatology.1 Topical corticosteroids are 58 
the mainstay of atopic dermatitis treatment and used for other skin conditions such as psoriasis, where 59 
they are often required for months or years to control the disease and ultimately restore patients’ quality 60 
of life. Numerous TCS are now available in different preparations, concentrations and potencies; 61 
however, when used appropriately TCS efficacy and safety are well established.2-6 62 
The beneficial anti-inflammatory effects of TCS are complex, being largely mediated via the cytoplasmic 63 
steroid receptor and involving actions on circulating cellular and cytokine mediators of inflammation as 64 
well as on the peripheral vasculture.7 The use of TCS is tempered by consideration of local and less 65 
frequently encountered systemic side effects. Known local side effects include skin atrophy, skin striae, 66 
contact allergy, rosacea, acne, mild hypopigmentation and hypertrichosis. Rarely absorption through 67 
the skin can cause adrenal suppression, hyperglycaemia and glaucoma.8 The risk of developing side 68 
effects is related to the potency, preparation, frequency and duration of use as well as and the age of 69 
the patient and the size of the surface area that the TCS is being applied to, or whether the area is 70 
vascular or not. In clinical practice these side effects are uncommon when TCS are used within their 71 
guidance.  72 
There are two types of skin cancers: melanoma and non-melanoma (keratinocyte). Around 97% of skin 73 
cancers are non-melanoma (NMSC), comprising mainly of basal cell carcinomas (BCCs) or cutaneous 74 
squamous cell carcinomas (cSCCs). The incidence of NMSC is increasing worldwide9-13 with an 75 
estimated 2-3 million new cases of NMSC recorded each year.14 With respect to cutaneous malignant 76 
melanoma (CMM), this is the most serious form of skin cancer and has been increasing steadily in 77 
incidence over the past 30 years.15 Mortality due to CMM is much higher than that of NMSC.16  78 
There are several observational studies that have looked at the relative risk of developing skin cancer 79 
due to oral corticosteroid exposure.17-18 These studies have provided conflicting results as to whether 80 
corticosteroids are associated with an increased risk of skin cancer. Karagas et al.17 conducted a case-81 
control study on over 800 non-transplant cSSC and BCC patients.17 The authors found that oral 82 
glucocorticoids may increase the risk of non-melanoma skin cancers, whereas Baibergenova et al.  83 
found no association between non-melanoma skin cancers and oral corticosteroids in a follow-up study 84 
of a chemotherapy trial with 1051 study participants.18 These studies highlight the clinical equipoise that 85 
exists around the impact oral corticosteroids have on the risk of skin cancer. 86 
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There have been several epidemiological studies that have explored the risk of cancer specifically 87 
amongst atopic dermatitis patients. Hagwstromer et al. conducted a hospital-based study on 15 666 88 
patients with atopic dermatitis in Sweden between 1965 and 1999.19The authors reported men faced a 89 
50% increased risk of non-melanoma skin cancer during the first 10 years of follow-up, but this did not 90 
reach statistical significance. The authors did not look at the association between skin cancer and 91 
corticosteroid use.19   Wang et al. conducted a review of atopic dermatitis studies published before 2004 92 
and found no consistent associations were observed for skin cancers.20 This review did not look at the 93 
effect of TCS use on the risk of skin cancer. At present, it is not known what particular impact TCS have 94 
on the risk of skin cancer in the atopic dermatitis population. 95 
With regards the organ transplant population, it is well established that immunosuppression increases 96 
the risk of skin malignancy.21,22 This occurs when oral  corticosteroids are used, although most studies 97 
include patients treated with a combination of systemic immunosuppressants including azathioprine 98 
and calcineurin inhibitors.23,24  Oral corticosteroids are known to have an immunosuppressive effect, 99 
and TCS may have a local immunosuppressive effect.25,26 It is not known whether TCS may increase 100 
the risk of skin cancer through this mechanism.  101 
On the other hand, it is possible that treating skin inflammation with TCS may reduce the risk of skin 102 
cancer. Several systematic reviews and meta-analyses report the benefits of anti-inflammatory drugs 103 
in reducing the risk of cancer, including skin cancers.27,275,26 The management of certain types of 104 
inflammatory skin diseases includes the rationale that reducing inflammation reduces the risk of cSCC 105 
development in vulval and penile lichen sclerosus as well as hypertrophic lichen planus. It is also known 106 
that chronic inflammation is a risk for the development of cSCC, such as in chronic ulceration and the 107 
development Marjolin’s ulcer.29,307,28 This mainly holds true for cSCC but less is known about BCC and 108 
melanoma. .Therefore, overall TCS may decrease the risk of skin cancer in patients where TCS are 109 
used to treat inflammatory skin disease. 110 
To date, no published systematic review or meta-analysis have been performed to collate evidence on 111 
long-term TCS use on the risk of skin cancer. The review group examined MEDLINE and EMBASE, 112 
Prospero and JBI Database of Systematic Reviews and Implementation Reports and did not find any 113 
current or planned reviews on the same topic. Immunosuppression induced by TCS, either local or 114 
systemic, may allow these cancers to emerge from reduced  immunosurveillance. However, TCS may 115 
also reduce the risk of skin cancer in patients where TCS are used to treat inflammatory skin disease. 116 
With TCS use being one of the most commonly prescribed drugs in the clinical field of dermatology and 117 
the increasing incidence of skin cancer there is a need to review all current evidence about the possible 118 
association. The protocol for this systematic review has recently been published.3129 119 
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 120 
Review question 121 
The objective of this systematic review was to synthesize the available research evidence to determine 122 
the risk of skin cancer in patients on long-term use of topical corticosteroids.  123 
In people using long-term (more than once a week regular use over for one1 month or longer) topical 124 
corticosteroids what is the risk of developing skin cancer (clinically or histologically confirmed non-125 
melanoma skin cancer (keratinocyte carcinoma), basal cell carcinoma, cutaneous squamous cell 126 
carcinoma or melanoma)? 127 
Methods 128 
Inclusion criteria 129 
Participants 130 
This review considered studies that included people, of all ages, genders and ethnicities. Participants 131 
with HIV, transplant participants or participants with genetic diseases (for example Gorlin-Goltz 132 
syndrome) were also considered eligible for the review. 133 
 134 
Exposure of interest 135 
This review considered studies that evaluate long-term use of topical corticosteroids. We define here 136 
‘long-term’ as using TCS more than once a week for a month or longer. 137 
 138 
Outcome or response 139 
This review considered studies that included the following outcome measures: Non-melanoma skin 140 
cancer (NMSC) (new nomenclature keratinocyte carcinoma), cutaneous squamous cell carcinoma 141 
(cSSC), basal cell carcinoma (BCC) or melanoma skin cancer. These outcomes could be measured by 142 
a clinical diagnosis and where available histological confirmation. Pre-cursors such as Bowen’s disease 143 
were considered secondary outcomes. 144 
 145 
Study types 146 
This review considered analytical comparative observational studies including prospective and 147 
retrospective cohort studies, case-control studies and cross-sectional studies.  148 
Search strategy 149 
The search strategy aimed to identify both published and unpublished studies. A three-step search 150 
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strategy was utilized in this review. An initial limited search of MEDLINE and EMBASE was undertaken 151 
followed by an analysis of the text words contained in the title and abstract, and of the index terms used 152 
to describe the article. A second search using identified key words and index terms was used to develop 153 
a comprehensive search strategy. The search strategy for MEDLINE is detailed in Appendix 1. Studies 154 
published in all languages were included.  155 
 156 
Information Sources 157 
The electronic databases searched included: MEDLINE, EMBASE and LILACS all from inception to 158 
16th February 20169th November 2017. The search strategy for MEDLINE and LILACS are detailed in 159 
Appendix 1 and 2 respectively. The search for unpublished studies included: EThOS at the British 160 
library (http://ethos.bl.uk); Drug Consumption Database (http://www.imi-161 
protect.eu/frameworkRep.shtml); .VigiBase (http://www.umc-162 
products.com/DynPage.aspx?id=73590&mn1=1107&mn2=1132 163 
http://www.umc-products.com/DynPage.aspx?id=73567&mn1=1107&mn2=1132&mn3=6052) and 164 
PROTECT ADR Database (http://www.imi-protect.eu/methodsRep.shtml) 165 
 166 
Study selection 167 
Following the search, all identified citations were collated and uploaded in EndNote and duplicates 168 
removed. Titles and abstracts were then screened by two independent reviewers (SR and EBT) for 169 
assessment against the inclusion criteria for the review. The full text of selected citations were 170 
retrieved and assessed independently by two reviewers (SR and EBT) in detail against the inclusion 171 
criteria. Full text studies that did not meet the inclusion criteria were excluded and reasons for 172 
exclusion were provided. Any disagreements between SR and EBT were resolved by discussion with 173 
reviewers JLB and FBH. 174 
Results 175 
Description of studies 176 
Following a comprehensive and systematic literature search of the identified databases, 21981703 177 
results were found (after excluding 27 duplicates). Titles and abstracts were then reviewed against 178 
the inclusion criteria and a further 25201 duplicates were concurrently removed. A total of 521 articles 179 
were obtained for full review and reasons for exclusion are detailed in Figure 1. We contacted the 180 
authors for one study in order to clarify TCS exposure; as their study was the most relevant to our 181 
research question.320 Unfortunately we got no response from the authors. No studies were found 182 
which met the inclusion criteria.  Meta-synthesis of findings was therefore not possible.  183 
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Figure 1: search results  184 
Data extraction, Critical appraisal and Data synthesis 185 
As no eligible studies were identified, the process of data extraction, appraisal and synthesis as 186 
outlined in the a priori protocol (JBISRIR-2016-003226) were not required. 187 
 188 
Findings of the review 189 
No studies which met the inclusion criteria were found in this systematic review. 190 
Discussion 191 
The overall objective of this quantitative systematic review was to establish if there is an association 192 
between long-term TCS use and the risk of skin cancer. We hoped this review might be used to 193 
inform clinicians and patients of potential adverse effects of this treatment, or conversely to minimize 194 
unfounded fears of TCS use which is common and often called ‘steroid phobia’ in the dermatology 195 
community.331 196 
There were no relevant studies which meant that this objective was not achieved. Several papers 197 
were identified which included oral and genital sites;34-612-59 however, these are considered ‘special 198 
sites’ because  disease presentation and risk factors are different to that of other sites of the body and 199 
therefore a specific review would be needed in the context of this clinical area. A number of excluded 200 
studies merit discussion to place these findings, or lack of, in context in order to inform future 201 
research and current clinical evidence based practice. 202 
The study by Landi et al.320 was the only one study identified which had a primary objective of 203 
determining whether steroid treatment was associated with skin cancer. However this study did not 204 
meet our eligibility criteria as there was no information on frequency and duration of TCS exposure. 205 
The authors conducted a case-control study in Italy, from 1994 to 1999, which included patients with 206 
cutaneous malignant melanoma (cases) and those without the condition (controls); glucocorticoid 207 
(GC) exposure was measured. People with malignant melanoma were less likely to have used GCs 208 
(OR=0.39; 95% CI=0.20-0.74; n=362). To overcome confounding by indication, the authors assessed 209 
whether the association between GC use and melanoma could be affected by treatment for 210 
dermatologic diseases in comparison to treatment for more systemic health problems. The authors 211 
also explored whether the occurrence of melanoma varied by route of administration (oral vs. topical) 212 
and they took into account ascertainment bias by adjusting for frequency of moles removed in 213 
addition to other covariates. The authors concluded that people without melanoma were more likely to 214 
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have been exposed to glucocorticoid-based therapy than those with melanoma; there was no effect 215 
modification by reason for treatment or route of administration. Larger studies would be needed to 216 
confirm these findings. 217 
There were three studies which investigated the risk of skin cancer amongst people with 218 
dermatological conditions. Ming et al.620 conducted a case-control study in the US, between 1998 and 219 
2001, with 1378 NMSC cases and 1533 controls with other dermatologic conditions to explore 220 
whether people with NMSC are more likely to have had atopic dermatitis (AD) than those without 221 
NMSC. The authors report TCS use was a confounder for the association between AD and NMSC. 222 
After adjusting for age, sex, ethnicity and TCS use the odds of AD was 0.78 (96% CI 0.61, 0.98) for 223 
those who had NMSC compared to those who did not. The authors also conducted a secondary 224 
analysis and report the odds of being a TCS user was about 30% less in those with a NMSC as 225 
compared with those without a NMSC. However, again, no information on frequency of TCS use was 226 
available, a limitation cited by the authors. 227 
Chen et al.631 investigated the risk of different cancers in people with psoriasis using the Taiwan 228 
National Health Insurance Research Database. Skin cancer was associated with psoriasis, especially 229 
younger patients, however the risk did not vary by topical treatment use (all topical treatments were 230 
grouped together). Finally, a Dutch cohort study with over 13,000 eczema and psoriasis patients 231 
showed the risk of skin cancer is not increased in those taking coal tar compared to those taking 232 
dermatocorticosteroids (all steroid treatments were grouped together).642 233 
 234 
Limitations 235 
The inclusion criteria for this review focused on patients who were exposed to long-term TCS use 236 
(more than once a week for a month or longer). There were no studies whose primary objective was 237 
to investigate long-term TCS exposure per se, as opposed to any TCS use. It is therefore 238 
unsurprising that no study included information on both duration and frequency of use. We believe 239 
that using a specific definition of long-term use based on clinical experience was necessary to 240 
maximize the external validity of this review.  241 
Conclusion 242 
We did not find any studies that might help us establish if long-term TCS use is associated with skin 243 
cancer. Future research using primary care databases might give a better understanding regarding  244 
long-term use of TCS and skin cancer. 245 
Implications for practice 246 
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There was an absence of evidence identified in the review to make clinical recommendations. 247 
Implications for research 248 
There is a significant gap in the evidence base in the area of long-term TCS use and the risk of skin 249 
cancer, and therefore future research needs to be conducted to answer this important question. There 250 
are several published papers in the area of oral and genital sites, therefore a systematic review in this 251 
specific area could be of potential benefit to the dermatology community. 252 
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Appendix 1: Search Strategy for Medline using OVID 430 
 431 
1. Epidemiologic studies/ 432 
2. Exp Case-control studies/ 433 
3. Exp Cohort studies/ 434 
4. Epidemiologic$ stud$.mp. 435 
5. Case control stud$.mp. 436 
6. Cohort stud$.mp. 437 
7. Cohort analy$.mp. 438 
8. Follow up stud$.mp.  439 
9. Observational stud$.mp. 440 
10. Longitudinal.mp. 441 
11. Retrospective.mp. 442 
12. Cross sectional stud$.mp. 443 
13. Cross Sectional Studies/ 444 
14. Exp Observational Study/ 445 
15. Or/1-14 446 
16. Carcinoma, Basal Cell/ 447 
17. Neoplasms, Basal Cell/ 448 
18. Basal Cell Nevus Syndrome/ 449 
19. Basal cell carcinoma$.mp. 450 
20. Basal cell cancer$.mp. 451 
21. Basal cell neoplasm$.mp. 452 
22. Nodular BCC.mp. 453 
23. Naevoid BCC.mp. 454 
24. Gorlin syndrome.mp. 455 
25. Basal cell Epithelioma$.mp. 456 
26. Basalioma$.mp. 457 
27. BCC.mp. 458 
28. Rodent ulcer$.mp. 459 
29. Or/16-28 460 
30. Exp Neoplasms, Squamous cell/ 461 
31. Exp Carcinoma Squamous Cell/ 462 
32. Squamous cell carcinoma$.mp. 463 
33. Squamous cell cancer$.mp. 464 
34. Squamous cell neoplasm$.mp. 465 
35. Bowen disease.mp. 466 
36. Planocellular carcinoma$.mp. 467 
37. SCC.mp. 468 
38. Or/30-37 469 
39. Skin neoplasms/ 470 
40. NMSC.mp. 471 
41. Non melanoma skin cancer$.mp. 472 
42. Skin cancer$.mp. 473 
43. Skin tumo$.mp. 474 
44. Skin neoplasm$ 475 
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45. Exp Keratinocytes/ 476 
46. Keratinocytes.mp. 477 
47. Or/39-46 478 
48. Melanoma/ 479 
49. Melanoma.mp. 480 
50. Or/48-49 481 
 482 
51. topical corticosteroid$.mp. 483 
52. steroid$.mp. 484 
53. corticosteroid$.mp. 485 
54. exp Glucocorticoids/ 486 
55. alclometasone.mp. 487 
56. alclomethasone.mp. 488 
57. amcinonide.mp. 489 
58. beclometasone.mp. 490 
59. beclomethasone.mp. 491 
60. exp Beclomethasone/ 492 
61. betametasone.mp. 493 
62. betamethasone.mp. 494 
63. exp Betamethasone/ 495 
64. clobetasol.mp. 496 
65. exp Clobetasol/ 497 
66. clobetasone.mp. 498 
67. desonide.mp. 499 
68. exp Desonide/ 500 
69. desoximetasone.mp. 501 
70. exp Desoximetasone/ 502 
71. diflorasone.mp. 503 
72. diflucortolone.mp. 504 
73. exp Diflucortolone/ 505 
74. fludroxycortide.mp. 506 
75. flumetasone.mp. 507 
76. flumethasone.mp. 508 
77. exp Flumethasone/ 509 
78. fluocinolone.mp. 510 
79. exp Fluocinolone Acetonide/ 511 
80. fluocinonide.mp. 512 
81. exp Fluocinonide/ 513 
82. fluocortolone.mp. 514 
83. exp Fluocortolone/ 515 
84. flurandrenolide.mp. 516 
85. flurandrenolone.mp. 517 
86. exp Flurandrenolone/ 518 
87. fluticasone.mp. 519 
88. halcinonide.mp. 520 
89. exp Halcinonide/ 521 
90. halobetasol.mp. 522 
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91. halometasone.mp. 523 
92. hydrocortisone.mp. 524 
93. exp Hydrocortisone/ 525 
94. methylprednisolone.mp. 526 
95. exp methylprednisolone/ 527 
96. mometasone.mp. 528 
97. triamcinolone.mp. 529 
98. exp Triamcinolone/ 530 
99. Or/ 51-98 531 
100. 15 AND (29 OR 38 OR 47 OR 50) AND 99 532 
 533 
 534 
Appendix 2: Search strategy for LILACS 535 
break 536 
 537 
 538 
 539 
(("carcinoma basocelular" or "epitelioma basocelular" or "squamous cell" or "squamous cells" or 540 
"epitelioma espinocelular" or "basal cell" or "basal cells" or "rodent ulcer" or "rodent ulcers"  or 541 
basalioma or nmsc or "non melanoma skin cancer" or "non melanoma skin cancers" or bcc or "gorlin 542 
syndrome" or "bowen's disease" or "enfermedad de Bowen" or "planocellular carcinoma" or 543 
"planocellular carcinomas" or scc or melanoma$ or keratinocyte$ or "skin cancer" or "skin cancers" 544 
or "skin tumor" or "skin tumours" or "skin neoplasm" or "skin neoplasms") and (alclometasone or 545 
alclomethasone  or amcinonide or beclometasone or beclomethasone or betamethasone or 546 
betametasone or budesonide or clobetasol or clobetasone or desonide or desoximetasone or 547 
dexamethasone or diflorasone or diflucortolone or fluclorolone or fludroxycortide or flumethasone 548 
or flumetasone or fluocinolone or fluocinonide or fluocortin or fluocortolone or fluprednidene or 549 
flurandrenolide or flurandrenolone or fluticasone or halcinonide or halobetasol or halometasone or 550 
hydrocortisone or masipredone or methylprednisolone or mometasone or prednicarbate or 551 
triamcinolone or ulobetasol or ((topical or topica) and (steroid$ or corsticosteroid$ or 552 
corticoesteroide$ or corticoid$ or esteroide$ or glucocorticoid$)))) 553 
 554 
 555 
 556 
 557 
 558 
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